In a truly groundbreaking advancement for the national healthcare sector, Mubadala Bio has successfully launched the UAE‘s first locally manufactured hemodialysis products through its specialized subsidiary, Wellpharma, operating out of Abu Dhabi. This historic milestone dramatically enhances the domestic life sciences ecosystem, representing the very first time that vital hemodialysis concentrate solutions are being produced entirely within the country’s borders.
By localizing the production of these critical, life-sustaining medical supplies, the capital is taking decisive steps to secure its healthcare infrastructure, ensuring that hospitals and clinics have uninterrupted access to the therapies that vulnerable patients depend upon daily.
Addressing the Critical Need for Renal Care
The comprehensive launch introduces eight distinct, hospital-grade hemodialysis solutions specifically designed to support complex dialysis procedures for patients suffering from acute or chronic kidney failure. For individuals whose kidneys can no longer effectively filter dangerous toxins and excess fluids from the blood, hemodialysis is an absolute life-sustaining necessity, not an elective treatment.
During these rigorous, hours-long procedures, highly specialized dialysis solutions play an indispensable, critical role. They actively help restore the body’s delicate electrolyte balance while safely and efficiently removing accumulated waste products from the patient’s bloodstream. By relying on Wellpharma‘s state-of-the-art facilities in Abu Dhabi, the UAE is ensuring that these solutions meet the most stringent global medical standards right at home.
Empowering Domestic Healthcare Supply Chains
This ambitious operational leap is part of a much broader strategic vision to reduce reliance on imported pharmaceuticals and medical consumables. Highlighting the overarching importance of this development, Dr. Bakheet Al Katheeri, CEO of Mubadala‘s UAE Investments Platform and Chairman of Mubadala Bio, explained the long-term impact on the industry:
“Since the launch of Mubadala Bio in 2025, we have continued to make significant progress in advancing capabilities across the life sciences sector. The introduction of locally manufactured hemodialysis solutions marks an important milestone, given the critical role these products play within the healthcare ecosystem. We remain committed to supporting the continued development of strategic healthcare capabilities and strengthening access to essential medical products.”
Echoing the focus on supply chain resilience and patient safety, Dr. Essam Mohamed, Group CEO of Mubadala Bio, noted how this localized production directly benefits those receiving treatment across the nation:
“The launch of the new hemodialysis solutions marks an important milestone for us as well as for the wider healthcare sector in the UAE. By producing them locally, we are ensuring more consistent supply of critical therapies for patients who depend on dialysis treatments while reinforcing our capabilities in the production of essential and specialized hospital-based therapies.”
Advancing the Capital’s Life Sciences Ambitions
Since its official inception, Mubadala Bio has been tasked with cultivating a world-class, globally competitive biopharma footprint. The integration of Wellpharma into this vision proves that the nation is moving rapidly from an importer of healthcare technology to a formidable producer and potential exporter.
Addressing the overarching economic and scientific goals driving these initiatives, Hamad Almarzooqi, Group Deputy CEO of Mubadala Bio, emphasized the structural importance of building comprehensive domestic value chains:
“Strengthening local manufacturing capabilities is central to supporting Abu Dhabi and the UAE’s ambition to become a leading hub for life sciences. Building a globally competitive sector requires strong domestic capabilities across the pharmaceutical value chain. The launch of locally manufactured hemodialysis solutions marks an important step in advancing these capabilities.”
Looking Toward a Healthier Future
As the prevalence of lifestyle-related conditions that lead to kidney issues continues to rise globally, having a secure, localized source for hemodialysis therapies provides the UAE with a massive strategic advantage. The successful rollout of these eight solutions by Wellpharma serves as a powerful testament to the capabilities of Abu Dhabi‘s industrial sector.
Backed by the formidable resources and strategic foresight of Mubadala, this development not only guarantees a lifeline for thousands of patients but also firmly cements the nation’s position as a pioneering powerhouse in the rapidly evolving Middle Eastern life sciences arena.
